Cellectricon provides AstraZeneca with high throughput drug screening platfom
Cellectricon, Swedish provider of screening solutions for drug discovery, is providing AstraZeneca with its groundbreaking high throughput platform, Dynaflow HT, for ion channel screening.
Cellectricon, Swedish provider of screening solutions for drug discovery, is providing AstraZeneca with its groundbreaking high throughput platform, Dynaflow HT, for ion channel screening.
The two companies began collaborating in May 2006, aiming to find a solution to major bottlenecks in ligand gated ion channel screening. Cellectricon says the results from this collaboration have successfully demonstrated the performance of its cell-based microfluidic screening platform, the Dynaflow HT System, which will become commercially available in 2009.
The Swedish biotech company employs novel microfluidic technologies to produce completely new types of assay and devices with superior performance characteristics and robustness. For example, used in pre-clinical pharmaceutical development, the Cellaxess HT System enables high throughput RNAi screening and greatly advances ion channel drug discovery.